This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Forest Laboratories urges US judge to dismiss Bystolic pay-for-delay lawsuit

By Michael Acton ( December 14, 2021, 23:27 GMT | Insight) -- Lawyers for Forest Laboratories — now part of Allergan — urged a US judge to dismiss a lawsuit accusing the company of striking illegal pay-for-delay patent settlements with other drugmakers to delay the market entry of generic versions of beta blocker Bystolic. During a lengthy hearing, Judge Lewis Liman at the US District Court for the Southern District of New York rigorously questioned lawyers for the plaintiffs and the defendants on why he should or shouldn't allow the case to pass the motion-to-dismiss stage. Lawyers for Forest Laboratories — now part of Allergan — urged a US judge in New York today to dismiss a lawsuit accusing the company of striking illegal pay-for-delay patent settlements with other drugmakers to delay the market entry of generic versions of beta blocker Bystolic....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections